Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using GLP-1Rs such as Ozempic or Wegovy.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Semaglutide Market Forecast and Competitive Landscape Report 2025-2033 Featuring Novo Nordisk, Eli Lilly and Co, AstraZeneca, Biocon, Johnson and Johnson, Pfizer, AbbVie, and Sanofi ...